A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding no longer available

Conditions

Hepatitis C

Interventions

DRUG: Elbasvir/grazoprevir

Sponsor

University of California, Los Angeles

Collaborators

[object Object]